Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Pharmacophore modeling and virtual screening for the discovery of new type 4 cAMP phosphodiesterase (PDE4) inhibitors.

Niu M, Dong F, Tang S, Fida G, Qin J, Qiu J, Liu K, Gao W, Gu Y.

PLoS One. 2013 Dec 10;8(12):e82360. doi: 10.1371/journal.pone.0082360. eCollection 2013.

2.

Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).

Cameron RT, Coleman RG, Day JP, Yalla KC, Houslay MD, Adams DR, Shoichet BK, Baillie GS.

Biochem Pharmacol. 2013 May 1;85(9):1297-305. doi: 10.1016/j.bcp.2013.02.026. Epub 2013 Mar 5.

3.

Phosphodiesterase 4 and its inhibitors in inflammatory diseases.

Jin SL, Ding SL, Lin SC.

Chang Gung Med J. 2012 May-Jun;35(3):197-210. Review.

PMID:
22735051
4.

Structure based virtual screening to identify selective phosphodiesterase 4B inhibitors.

Gangwal RP, Damre MV, Das NR, Dhoke GV, Bhadauriya A, Varikoti RA, Sharma SS, Sangamwar AT.

J Mol Graph Model. 2015 Apr;57:89-98. doi: 10.1016/j.jmgm.2015.01.007. Epub 2015 Jan 22.

PMID:
25687765
5.

Multiple pharmacophore models combined with molecular docking: a reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity.

Chen Z, Tian G, Wang Z, Jiang H, Shen J, Zhu W.

J Chem Inf Model. 2010 Apr 26;50(4):615-25. doi: 10.1021/ci9004173.

PMID:
20353193
7.

Discovery of triazines as potent, selective and orally active PDE4 inhibitors.

Gewald R, Grunwald C, Egerland U.

Bioorg Med Chem Lett. 2013 Aug 1;23(15):4308-14. doi: 10.1016/j.bmcl.2013.05.099. Epub 2013 Jun 10.

PMID:
23806553
8.

Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.

Plummer MS, Cornicelli J, Roark H, Skalitzky DJ, Stankovic CJ, Bove S, Pandit J, Goodman A, Hicks J, Shahripour A, Beidler D, Lu XK, Sanchez B, Whitehead C, Sarver R, Braden T, Gowan R, Shen XQ, Welch K, Ogden A, Sadagopan N, Baum H, Miller H, Banotai C, Spessard C, Lightle S.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3438-42. doi: 10.1016/j.bmcl.2013.03.072. Epub 2013 Mar 28.

PMID:
23582272
9.

Discover natural compounds as potential phosphodiesterase-4B inhibitors via computational approaches.

Li J, Zhou N, Liu W, Li J, Feng Y, Wang X, Wu C, Bao J.

J Biomol Struct Dyn. 2016 May;34(5):1101-12. doi: 10.1080/07391102.2015.1070749. Epub 2016 Jan 20.

PMID:
26159554
10.

Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.

Nankervis JL, Feil SC, Hancock NC, Zheng Z, Ng HL, Morton CJ, Holien JK, Ho PW, Frazzetto MM, Jennings IG, Manallack DT, Martin TJ, Thompson PE, Parker MW.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7089-93. doi: 10.1016/j.bmcl.2011.09.109. Epub 2011 Oct 5.

PMID:
22030030
11.

Pharmacophore modeling, 3D-QSAR, and docking study of pyrozolo[1,5-a]pyridine/4,4-dimethylpyrazolone analogues as PDE4 selective inhibitors.

Tripuraneni NS, Azam MA.

J Mol Model. 2015 Nov;21(11):289. doi: 10.1007/s00894-015-2837-4. Epub 2015 Oct 26.

PMID:
26499496
12.

A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors.

Tripuraneni NS, Azam MA.

J Biomol Struct Dyn. 2016 Nov;34(11):2481-92. doi: 10.1080/07391102.2015.1119732. Epub 2016 Apr 12.

PMID:
26587754
13.

Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases.

Souness JE, Rao S.

Cell Signal. 1997 May-Jun;9(3-4):227-36. Review.

PMID:
9218122
14.

Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs.

Burnouf C, Pruniaux MP.

Curr Pharm Des. 2002;8(14):1255-96. Review.

PMID:
12052219
15.

Phosphodiesterase inhibitors in the treatment of inflammatory diseases.

Page CP, Spina D.

Handb Exp Pharmacol. 2011;(204):391-414. doi: 10.1007/978-3-642-17969-3_17. Review.

PMID:
21695650
16.

Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.

Song G, Zhao D, Hu D, Li Y, Jin H, Cui Z.

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4610-4. doi: 10.1016/j.bmcl.2015.08.043. Epub 2015 Aug 21.

PMID:
26320621
17.

Phosphodiesterase inhibitors in airways disease.

Fan Chung K.

Eur J Pharmacol. 2006 Mar 8;533(1-3):110-7. Epub 2006 Feb 2. Review.

PMID:
16458289
18.

Small molecule allosteric modulators of phosphodiesterase 4.

Gurney ME, Burgin AB, Magnusson OT, Stewart LJ.

Handb Exp Pharmacol. 2011;(204):167-92. doi: 10.1007/978-3-642-17969-3_7. Review.

PMID:
21695640
19.
20.

Supplemental Content

Support Center